



Australian Government

Department of Health

**Expert Review Implementation Committee
(ERIC)**

Minutes of the Meeting of 30 June 2017

9.00am, Executive Boardroom

Member participants

Adj Prof John Skerritt (Chair)	Deputy Secretary, Health Products Regulation Group
Adj Prof Tim Greenaway	Chief Medical Adviser
Ms Jenny Francis	Principal Legal and Policy Adviser
Ms Adriana Platona	FAS, Medical Devices and Product Quality Division
Dr Larry Kelly	FAS, Medicines Regulation Division
Mr David Weiss	FAS, Regulatory Practice and Support Division
Mr Daniel McCabe	FAS, Information Technology Division

Apologies

Nil

Attendees

Dr Mark McDonald	AS, Regulatory Reforms Branch
s22(1)	
Ms Nicole McLay	AS, Regulatory Services and Improvement Branch
s22(1)	
Mr Anthony O'Connor (item 3)	AS, Regulatory Knowledge and Technology Services Branch
s22(1)	
Dr Rochelle Christian (item 4)	AS, Scientific Evaluation Branch
s22(1)	
Dr Jane Cook (item 6)	AS, Pharmacovigilance and Special Access Branch
Mr Pio Cesarin (item 7)	AS, Regulatory Practice, Education & Compliance Branch
s22(1)	
Ms Lyndall Soper (items 8 and 9)	AS, Complementary & OTC Medicines Branch
s22(1)	

1. Minutes of previous meeting

Minutes from the meeting of 16 June 2017 were accepted as an accurate reflection of the meeting.

s22(1)




Papers for consideration

s22(1)



s22(1)



8. Consultation analysis – Options for the future regulation of ‘low risk’ products

The ERIC was provided with the preliminary analysis of submissions to the public consultation ‘Options for the future regulation of ‘low risk’ products’ and the proposed next steps for this project.

The public consultation paper was published on the TGA website for six weeks (31 March – 12 May). In addition, key stakeholders were also specifically invited to comment. These stakeholders include peak industry bodies and health professional interest groups. A total of 1028 submissions were received, including 65 submissions from organisations. A number of submissions commented on the potential reforms to homoeopathic products.


The ERIC paper included:

- a table of organisations that provided a submission (with key organisations highlighted);
- a tally of responses by option for each ‘low risk’ product type; and
- a summary of key stakeholder submissions.

In many cases the options proposed for the future regulation of ‘low risk’ products were not mutually exclusive and several options could be implemented simultaneously for a particular product type. Despite this, many stakeholders simply indicated support for one option. s22(1)



s47C



s47C



ERIC:

- noted the summary of public consultation; and
- noted the next steps for “Options for the future regulation of ‘low risk’ products”.

s22(1)



S22(1)

